TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction of tympanic membranes with fluid or air-fluid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention rates at 6 and 12 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: NGAL/hepcidin-25 ratio for risk of AKI-RRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: OHS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Component survival
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in child anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinically significant cancer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: re-conduction across the cavo-tricuspid isthmus (CTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perineal repair rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Major perineal injury rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Participants’ satisfaction with care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in outcomes in hospitalized COVID-19 patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FPCD/Wt ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective laxity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: max 13 C% dose/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 13 C% cum dose at 120 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: regulation of fatty acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ATP biosynthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: regulation of apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymmetric pivot shift
Endpoint domain: Adverse events/effects
Primary endpoint: Graft rupture
Endpoint domain: Adverse events/effects
Primary endpoint: Screening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBFP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Submission of alcohol-negative urine sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality status
Endpoint domain: Mortality/survival
Primary endpoint: Retention in care at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of RRTI returning to normal standard level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of fat oxidized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean self-perception of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: mRS score 0-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative fentanyl consumption at 22 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores at T2T5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to initiation of PCIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three-year DFS
Endpoint domain: Mortality/survival
Primary endpoint: Visual analog score (VAS) for soft tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity of lipoprotein‐associated phospholipase A2 (Lp‐PLA₂)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: levels of interleukin (IL)‐1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: activity of NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SDM Process scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discussion of CRC screening
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Intention to follow through with preferred approach
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bowel function deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean lung ultrasound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: symphysis-levator distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levator hiatal narrowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensity of sexual pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: noncardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Global Impression‐severity of illness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of VCSS and VDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Levels of serum Bax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of Bcl-2 and Caspase-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postural variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to work at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: clinical endometritis
Endpoint domain: Adverse events/effects
Primary endpoint: new-onset AFF
Endpoint domain: Adverse events/effects
Primary endpoint: multistep hepatocarcinogenesis
Endpoint domain: Mortality/survival
Primary endpoint: MAC-BAR of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchopulmonary dysplasia-free survival at 36 weeks' postmenstrual age
Endpoint domain: Mortality/survival
Primary endpoint: Rate of adverse event-related discontinuations
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical or microbiological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients reaching CMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total-hip bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in femoral-neck bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical fracture events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean total translation at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid screening rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A1c screening rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aEEG score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of mature sleep-wake cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10% improvement in mean exam score
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difficult LMAS placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP at 6 AM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: ∆IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: RNFLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: maintenance of physical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to try and liking for tomato
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression from paroxysmal AF to persistent atrial tachyarrhythmia
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of OBL areas in the anterior lenticule plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of OBL areas in the posterior lenticule plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean gray values of the OBL in the posterior lenticule plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of discussions about suicide
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improved reading performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binge eating symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performed work (number of chest compressions x compression depth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bone area in the distal tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trabecular bone area in the tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower leg muscle density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in LV mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HbF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in knowledge regarding behavior management of child patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior management skill of dental undergraduate students
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular Ectopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PBSFS score of 3 or 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRQoL total scale score improvements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CSMS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life based on Rhinoconjunctivitis Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in Ogilvie dysphagia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental component scores of the Short Form-36 QoL questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Radiologically confirmed POH recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Vancouver scar scale (VSS) mean decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dermal and collagen bundle thickness decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Euthyroid state maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: recurrent AF, HF and acute coronary syndrome
Endpoint domain: Mortality/survival
Primary endpoint: rehospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of patients reporting pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mild fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Symptom interference with daily functions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Attainment of employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Usage of FIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FIT positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Subsequent colonoscopy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: postoperative early pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative esthetics satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain interference scores for work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain interference scores for activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle strength of elbow extension and pronation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRTEE pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of multiple ERCP sessions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of blade-to-skin contacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of blade-to-skin contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of touches >0.5 seconds duration
Endpoint domain: Adverse events/effects
Primary endpoint: en-masse retraction duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BRS (Baroreflex Sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prevalence of unhealthy food advertisements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean duration of severe oral mucositis (OM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of POR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients recommended intensive surveillance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sufficient circulating 25(OH)D3 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: neutrophil-to-lymphocyte ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SSE frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of suspicious lesions and melanomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: chronic kidney disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Grade 3-4 mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Impaired long-term quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood in sputum
Endpoint domain: Adverse events/effects
Primary endpoint: CSMS improvement over placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial efficacy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum voltage of the masseter muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: plantar pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: complete clearance of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mother-infant interaction quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Weight gain in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of acute nociception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: child-reported overall pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caregiver-reported worst pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: m-PPT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inverter/dorsiflexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAIT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume gained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of fistula development
Endpoint domain: Adverse events/effects
Primary endpoint: Canine palatal bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: global assessment score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reduction of hair loss indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of injection site and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody responses to vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transplacental transfer of maternal antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: severity of hypoxic respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worsening extrapulmonary MOF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 5-hydroxytryptophan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBD-related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Duration of remission (DoR)
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability of TES
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total amount of oxaliplatin received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median relative dose intensity (RDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment cycles of oxaliplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETT insertion depth correlation with birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac vagal activity after breakfast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Surgeon confidence in planning for extraction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median survival on CNI-free immunosuppression
Endpoint domain: Mortality/survival
Primary endpoint: Referral to a physician
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICD replacement acceptance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: muscle strength (peak torque)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: LA increases in plasma, erythrocyte, and PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PBMC LA4 CL increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BLISS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BED10(achieved) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombolysis in MI (TIMI) flow grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No-reflow or slow flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial blush grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heel ultrasound BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: risk of fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: long-term efficacy and durability of RDN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time in blood pressure target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Methane (CH4) production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ammonia nitrogen (NH3-N) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dry matter degradability of fermentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: abdominal pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete spontaneous bowel movement frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: APC+1 responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of the TrA and IO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Risk of Anorexia nervosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes